ArticleWorld journal of pediatrics : WJP2026
Efficacy and safety of tocilizumab in the chronic phase of febrile infection-related epilepsy syndrome: a retrospective cohort study.
Article in World journal of pediatrics : WJP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundFebrile infection-related epilepsy syndrome (FIRES) is a rare and severe epileptic encephalopathy characterized by refractory seizures following a febrile infection. FIRES is a subtype of new-onset refractory status epilepticus with an unknown etiology. Tocilizumab is an interleukin-6 receptor antagonist which has been recommended as an anti-inflammatory treatment for the acute phase of FIRES. However, the efficacy of tocilizumab for the chronic phase of FIRES remains unclear. This study aimed to analyze the efficacy and safety of tocilizumab in the treatment of pediatric patients with FIRES during the chronic phase.
methodsWe conducted a retrospective cohort study in pediatric patients with FIRES during the chronic phase who received tocilizumab treatment. The primary outcome was the response rate at 16 weeks after tocilizumab initiation, defined as the proportion of pediatric patients who achieved a 50% or greater reduction in seizure frequency. Secondary outcomes included the response rate at 28 weeks, treatment-related adverse events, and changes in the modified Rankin Scale (mRS) scores. The response rate to tocilizumab treatment, incidence of adverse reactions and factors related with the efficacy of tocilizumab were analyzed.
resultsTwenty-seven pediatric patients with chronic-phase FIRES were included. The median duration of seizures at tocilizumab initiation was 16 months [interquartile range (IQR): 6-34 months]. All patients received a median of four (IQR: 3-6) doses of tocilizumab. Most patients (81.5%, 22/27) did not require additional anti-seizure medications during the entire treatment period. After 16 weeks of treatment, 63.0% (17/27) of patients achieved a 50% or greater reduction in seizure frequency, and 7.4% (2/27) were seizure free; 70.4% (19/27) of the patients showed improvements in mRS scores. After 28 weeks, the response rate was 48.1% (13/27). The most common adverse events were neutropenia (33.3%, 9/27) and infections (14.8%, 4/27).
conclusionsTocilizumab is effective in the treatment of epilepsy in the chronic phase of FIRES. Tocilizumab can reduce the seizure frequency in pediatric patients with FIRES and is relatively safe.
Indexed as
Identifiers
42696242What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.